Agliardi, Giulia
Liuzzi, Anna Rita
Hotblack, Alastair http://orcid.org/0000-0002-6214-2296
De Feo, Donatella
Núñez, Nicolás http://orcid.org/0000-0003-3837-270X
Stowe, Cassandra L.
Friebel, Ekaterina
Nannini, Francesco http://orcid.org/0000-0001-9589-5107
Rindlisbacher, Lukas
Roberts, Thomas A. http://orcid.org/0000-0003-0385-1057
Ramasawmy, Rajiv
Williams, Iwan P.
Siow, Bernard M. http://orcid.org/0000-0002-8687-8783
Lythgoe, Mark F.
Kalber, Tammy L. http://orcid.org/0000-0002-3378-3748
Quezada, Sergio A. http://orcid.org/0000-0002-9763-1700
Pule, Martin A.
Tugues, Sonia
Straathof, Karin http://orcid.org/0000-0001-9673-8568
Becher, Burkhard http://orcid.org/0000-0002-1541-7867
Funding for this research was provided by:
Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung
EC | Horizon 2020 Framework Programme (602239)
Article History
Received: 8 March 2020
Accepted: 11 December 2020
First Online: 19 January 2021
Competing interests
: B.B. holds shares to Gaeta Therapeutics and a patent on the use of IL-12 tumor targeting in combination with check-point inhibition. The patent is named “COMBINATION MEDICAMENT COMPRISING IL-12 AND AN AGENT FOR BLOCKADE OF T-CELL INHIBITORY MOLECULES FOR TUMOUR THERAPY” with publication number: 20150017121. M.A.P. owns stock, receives salary contribution and research funding from Autolus Ltd. M.A.P. is entitled to a share of royalties earned from patents filed by UCL on his behalf. All other authors declare no competing interests.